Antiviral drugs are a class of drugs used to prevent and treat viral infections. It can inhibit viral replication enzymes in vitro, inhibit viral replication or reproduction in infected cells or animals, and is a clinically useful drug for treating viral diseases. Viruses are the smallest of pathogenic microorganisms. A protein shell and membrane surround it with the nucleic acid.
The Southeast Asia antiviral drug market has the potential to grow with propelling CAGR in the forecast period from 2020-2027. The main factors for the growth of the market are increased cases of viral infections, storage in public medical institutions, and coordination measures for the proper use and circulation of antiviral drugs.
With the acceleration of global R&D of anti-AIDS drugs, the trend of AIDS treatment is changing. At present, the universal antiviral therapy is gradually entering the era of integrase inhibitors, and fixed-dose compound preparations have become the trend of future treatment. Integrase inhibitors have four primary characteristics: more potent antiviral effects, smaller side effects, fewer drug interactions, and less resistance.
Viral diseases are a type of common conditions, which have the characteristics of high morbidity, rapid spread, widespread and significant variability. Although viral vaccines can reduce the incidence of certain viral diseases such as polio and measles, most viruses currently have neither effective vaccines nor effective therapeutic drugs, which is extremely harmful to humans.
Moreover, with the development of antiretroviral drugs, and the introduction and clinical application of highly active antiretroviral therapy characterized by the combination of multiple medications, AIDS has become a terrible disease into a manageable chronic illness. People living with HIV who insist on treatment with anti-AIDS drugs can not only maintain a good life and work status but also prolong their lives.
Furthermore, with the accelerated development and marketing of anti-HIV drugs worldwide, the trend of HIV treatment is gradually changing. At present, global antiviral therapy is slowly entering the era of integrase inhibitors (having more potent antiviral effects, fewer drug interactions, and less resistance. The fixed-dose compound preparations are also becoming the mainstream way of antiviral treatment.
Regardless of the duration of infection or the level of CD4 in patients, generally speaking, after HIV enters the human body, it will cause damage to multiple organs throughout the body. HIV- infected patients with viral hepatitis will make the disease progress more rapidly, including cirrhosis, hepatocellular carcinoma, liver failure, etc. Antiviral therapy can delay liver disease progression by rebuilding immune function, reducing immune activation, and inflammatory response. Cardiovascular disease is HIV important cause of death in infected people; 10 % antiviral therapy may reduce this risk.
From a worldwide perspective, most patients infected with the pandemic influenza virus continue to show typical flu symptoms, even in the absence of any medical treatment, they will fully recover within a week. The antiviral drug given to the coronavirus patient; it will help in increasing the immune system. Its preparation relates to a new dosage form and preparation method of Isoprinosine medicine.
Based on the drug class, the Southeast Asia antiviral drug market segment into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others. The Reverse Transcriptase Inhibitors segment accounted for the largest share in the Southeast Asia antiviral drug market. The unique function of viral reverse transcriptase in the viral life cycle makes it an essential target for antiviral therapy. Reverse transcriptase inhibitors can individually act on viral reverse transcriptase and inhibit its activity, thereby treating AIDS.
Based on the application, the Southeast Asia antiviral drug market classified into HIV, Hepatitis, Influenza. The Hepatitis segment is estimated to dominates the maximum share of Southeast Asia antiviral drug market in the forecast period. Hepatitis B antiviral therapy refers to the treatment of hepatitis B patients during disease, to inhibit viral replication by drug formulation, and ultimately cleared the hepatitis B virus. It is possible to control a class of drugs collectively disease progression. Antiviral therapy is the fundamental treatment method for chronic hepatitis B, and patients who comply with antiviral treatment can treat with hepatitis B antiviral drugs to achieve disease recovery.
Based on the type, the Southeast Asia antiviral drug bifurcated into Branded, Generic. Branded dominates the largest market share in the Southeast Asia antiviral drug market. It is mainly owing to the goodwill and presence the brands have created in the mind of the people. Thus, the demand for the branded antiviral drugs is propelling the market share of the Southeast Asia antiviral drug market. Moreover, consumers believe that branded antiviral drugs are safer to consume than generic medicines.
Based on geography, the Southeast Asia antiviral drug market segmented Indonesia, Malaysia, Philippines, Thailand, Vietnam, Singapore, Myanmar, Rest of Southeast Asia. Vietnam is capturing the largest market share of the Southeast Asia antiviral drug market. It is mainly due to the increasing adoption of viral diseases, rising healthcare infrastructure facilities, and the availability of generic and branded drugs that are propelling the market.
Companies such as Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories and others are key players in the Southeast Asia antiviral drug market.
By Drug Class